nicht-klinischen/präklinischen Studien für den Menschen wird 
derzeit untersucht. 
 
   Für weitere Informationen kontaktieren Sie bitte: 
 
 
 
 
  Dr. Peer Nils Schröder 
   Head of Corporate Communications & Investor Relations 
  Telefon                                   +41 61 606 1102 
  E-Mail         media_relations@basilea.com 
                  investor_relations@basilea.com 
 
 
   Diese Pressemitteilung ist unter www.basilea.com abrufbar. 
 
   Quellenangaben 
 
   Hinweis: Aus Gründen der Lesbarkeit wurde in der Pressemitteilung 
die männliche Form ,,Patienten" gewählt, jedoch beziehen sich 
die 
 
   Angaben auf Angehörige aller Geschlechter. 
 
 
   1. FIDES-01: ClinicalTrials.gov-Identifier: NCT03230318 
 
   2. Topline-Ergebnisse für die Kohorte 1 der FIDES-01-Studie wurden am 
      10. Februar 2021 veröffentlicht (siehe Pressemitteilung 
      https://www.basilea.com/news/news/basilea-gibt-positive-topline-ergebnisse-aus-phase-2-studie-fides-01-mit-derazantinib-bei-patienten-mit-gallengangkrebs-icca-und-fusionen-des-fgfr2-gens-bekannt 
      ) 
 
   3. T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a 
      novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), 
      e0162594 
 
   4. R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in 
      cancer: Molecular biology and new drugs. Critical Reviews in 
      Oncology/Hematology 2017 (113), 256-267 
 
   5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: 
      Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer 
      Research 2016 (22), 259-267 
 
   6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A 
      dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. 
      Molecular Cancer Therapeutics 2019 (18), 12 Supplement, pp. LB-C12 
 
   7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 
      receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy 
      of Cancer 2017, 5:53 
 
   8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms 
      tumor-infiltrating macrophages and improves response to T cell checkpoint 
      immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 
      5057-5069 
 
   9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells 
      from reaching tumor cells and limit the efficacy of anti--PD-1 treatment. 
      Proceedings of the National Academy of Science of the United States of 
      America 2018 (115), E4041-E4050 
 
  10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib 
      (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive 
      intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 
      165-171. ClinicalTrials.gov-Identifier: NCT01752920 
 
  11. FIDES-02: ClinicalTrials.gov-Identifier: NCT04045613 
 
  12. FIDES-03: ClinicalTrials.gov-Identifier: NCT04604132 
 
  13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in 
      cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the 
      rise. The Oncologist 2016 (21), 594-599 
 
  14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. ABC-06 | A randomised phase 
      III, multi-centre, open-label study of Active Symptom Control (ASC) alone 
      or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients 
      (pts) with locally advanced/metastatic biliary tract cancers (ABC) 
      previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. 
      Journal of Clinical Oncology 2019 (37), Supplement, Abstract 4003 
 
 
   Anhang 
 
 
   -- Pressemitteilung (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/5476f411-05ef-4f28-ade4-24052d0e7c86

(END) Dow Jones Newswires

March 24, 2021 02:15 ET (06:15 GMT)